{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:40:59Z","timestamp":1791052859748,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"H\u00f4pitaux Universitaire du Grand Ouest","award":["AAP JCM2020"],"award-info":[{"award-number":["AAP JCM2020"]}]},{"DOI":"10.13039\/501100018950","name":"Rennes University Hospital","doi-asserted-by":"crossref","award":["CORECT Visiting Grant 2020"],"award-info":[{"award-number":["CORECT Visiting Grant 2020"]}],"id":[{"id":"10.13039\/501100018950","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24-AR-063129"],"award-info":[{"award-number":["K24-AR-063129"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s10067-021-05598-7","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T02:03:35Z","timestamp":1611453815000},"page":"1611-1616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["How do patients define Raynaud\u2019s phenomenon? Differences between primary and secondary disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7924-0012","authenticated-orcid":false,"given":"Susan L.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Alore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Pauling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,24]]},"reference":[{"issue":"6","key":"5598_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","volume":"375","author":"F Wigley","year":"2016","unstructured":"Wigley F, Flavahan N (2016) Raynaud\u2019s phenomenon. N Engl J Med. 375(6):556\u2013565","journal-title":"N Engl J Med."},{"issue":"1","key":"5598_CR2","first-page":"70","volume":"20","author":"H Maricq","year":"1993","unstructured":"Maricq H, Carpentier P, Weinrich M, Keil J, Franco A, Drouet P et al (1993) Geographic variation in the prevalence of Raynaud\u2019s phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol. 20(1):70\u201376","journal-title":"J Rheumatol."},{"issue":"3","key":"5598_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/rheumatology\/kez522","volume":"59","author":"M Hughes","year":"2020","unstructured":"Hughes M, Khanna D, Pauling J (2020) Drug initiation and escalation strategies of vasodilator therapies for Raynaud\u2019s phenomenon: Can we treat to target? Rheumatology (Oxford). 59(3):464\u2013466","journal-title":"Rheumatology (Oxford)."},{"issue":"12","key":"5598_CR4","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","volume":"38","author":"J Pauling","year":"2019","unstructured":"Pauling J, Hughes M, Pope J (2019) Raynaud\u2019s phenomenon\u2014an update on diagnosis, classification and management. Clin Rheumatol. 38(12):3317\u20133330","journal-title":"Clin Rheumatol."},{"issue":"9","key":"5598_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/acr.23475","volume":"70","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S (2018) Multinational qualitative research study exploring the patient experience of Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Care Res. 70(9):1373\u20131384","journal-title":"Arthritis Care Res."},{"issue":"10103","key":"5598_CR6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"C Denton","year":"2017","unstructured":"Denton C, Khanna D (2017) Systemic sclerosis. Lancet. 390(10103):1685\u20131699","journal-title":"Lancet."},{"issue":"5","key":"5598_CR7","first-page":"879","volume":"24","author":"H Maricq","year":"1997","unstructured":"Maricq H, Carpentier P, Weinrich M, Keil J, Palesch Y, Biro C, Vionnet-Fuasset M, Jiguet M, Valter I (1997) Geographic variation in the prevalence of Raynaud\u2019s phenomenon: a 5 region comparison. J Rheumatol. 24(5):879\u2013889","journal-title":"J Rheumatol."},{"issue":"1","key":"5598_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/rheumatology\/key026","volume":"58","author":"J Pauling","year":"2018","unstructured":"Pauling J, Saketkoo L, Matucci-Cerinic M, Ingegnoli F, Khanna D (2018) The patient experience of Raynaud\u2019s phenomenon in systemic sclerosis. Rheumatology (Oxford). 58(1):18\u201326","journal-title":"Rheumatology (Oxford)."},{"key":"5598_CR9","doi-asserted-by":"publisher","DOI":"10.4135\/9781483384436","volume-title":"Applied thematic analysis","author":"GMK Guest","year":"2012","unstructured":"Guest GMK, Namey EE (2012) Applied thematic analysis. SAGE, Thousand Oaks"},{"issue":"8","key":"5598_CR10","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1093\/rheumatology\/keaa037","volume":"59","author":"M Hughes","year":"2020","unstructured":"Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A (2020) Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology (Oxford). 59(8):2156\u20132158","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"5598_CR11","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/acr.23413","volume":"70","author":"A Lescoat","year":"2018","unstructured":"Lescoat A, Coiffier G, de Carlan M, Droitcourt C, Ballerie A, Cazalets C, Perdriger A, J\u00e9go P (2018) Combination of capillaroscopic and ultrasonographic evaluations in systemic sclerosis: results of a cross-sectional study. Arthritis Care Res. 70(6):938\u2013943","journal-title":"Arthritis Care Res."},{"issue":"6","key":"5598_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/art.40799","volume":"71","author":"A Lescoat","year":"2019","unstructured":"Lescoat A, Yelnik CM, Coiffier G, Wargny M, Lamotte C, Cazalets C, Belhomme N, Ballerie A, Hatron PY, Launay D, Perdriger A, Sobanski V, Hachulla E, J\u00e9go P (2019) Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: a multicenter cross-sectional study. Arthritis Rheumatol. 71(6):983\u2013990","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"5598_CR13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla E, Hatron PY, Carpentier P, Agard C, Chatelus E, Jego P, Mouthon L, Queyrel V, Fauchais AL, Michon-Pasturel U, Jaussaud R, Mathian A, Granel B, Diot E, Farge-Bancel D, Mekinian A, Avouac J, Desmurs-Clavel H, Clerson P, SEDUCE study group (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis. 75(6):1009\u20131015","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"5598_CR14","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/art.40242","volume":"69","author":"CP Denton","year":"2017","unstructured":"Denton CP, Hachulla \u00c9, Riemekasten G, Schwarting A, Frenoux JM, Frey A, le Brun FO, Herrick AL, on behalf of the Raynaud Study Investigators (2017) Efficacy and safety of selexipag in adults with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 69(12):2370\u20132379","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"5598_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/art.40481","volume":"70","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Saketkoo LA, Domsic RT (2018) Patient perceptions of the Raynaud\u2019s condition score diary provide insight into its performance in clinical trials of Raynaud\u2019s phenomenon: comment on the article by Denton et al. Arthritis Rheumatol. 70(6):973\u2013974","journal-title":"Arthritis Rheumatol."}],"updated-by":[{"DOI":"10.1007\/s10067-021-05620-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05598-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05598-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T20:22:52Z","timestamp":1627676572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05598-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,24]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5598"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05598-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10067-021-05620-y","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,24]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-021-05620-y","URL":"https:\/\/doi.org\/10.1007\/s10067-021-05620-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Pauling reports personal fees from Boehringer Ingelheim; grants, personal fees, and non-financial support from the Actelion Pharmaceuticals; personal fees from Sojournix Pharma, all outside the submitted work. Dr. Hughes reports speakers\u2019 fees from Actelion Pharmaceuticals. Dr. Khanna is a consultant to Acceleron, Abbvie, Actelion, Amgen, Bayer, BMS, Boehringer Ingelheim, CSL Behring, Corbus, Galapagos, Genentech\/Roche, GSK, Horizon, MitsubishiTanabe Pharma, Sanofi-Aventis, and United Therapeutics. He has stock options in Eicos Sciences, Inc. No other authors report conflicts of interest or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved with exempt status by the University of Michigan IRB (Study ID: HUM00175143; OHRP IRB Registration Number(s): IRB00000246).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data underlying this article will be shared on reasonable request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"N\/A","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}